Our goal is to identify novel therapeutic approaches for cancer that target the genetic mutations and altered signaling networks that are specific to cancer cells and their microenvironment. We use functional genomics applied to mouse and human systems (genetically engineered models, patient derived xenografts) to understand the signaling pathways and transcriptional networks that regulate the outcome of specific oncogenic mutations and to identify new approaches for cancer therapy. We have two primary disease interests: lung cancer and pediatric sarcomas.